Veraxa Biotech AG
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| J8L0.F | HURA | CTMX | PYXS | MGNX | HBP.TO | |
|---|---|---|---|---|---|---|
| Market cap | 123.17M | 133.65M | 525.14M | 208.45M | 228.68M | 74.85M |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | — | -3.5 | -5.1 | -1.6 | -2.4 | -8.9 |
| Price/book | -0.8 | 7.3 | 1.7 | 9.7 | 5.3 | 5.1 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −72.73% | −6.50% | −27.27% | −47.93% | +96.17% | −55.45% |
| Today | −1.02% | +0.59% | +0.42% | −0.85% | 0.00% | 0.00% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All J8L0.F news ›VERAXA Biotech and Secarna Pharmaceuticals Achieve Research Milestone in Antibody Oligonucleotide Conjugate (AOC) Alliance
Successful in vitro proof-of-concept study demonstrates the potential to create novel antibody-oligonucleotide conjugates (AOCs) by combining both parties’ technologies and expertise ZURICH, SWITZERLAND, and MARTINSRIED/MUNICH, GERMANY,…
VERAXA Biotech to Debut as a Publicly Traded Company Pioneering Next-Generation Cancer Therapies on June 11, 2026
Strengthened financial position with $27.5 million principal amount senior secured note financing and $50 million share purchase agreement to advance VERAXA’s pipeline of oncology drug candidates utilizing its novel BiTAC platform VERAXA…
VERAXA Biotech Announces Advancement of Novel Bispecific Antibody Drug Conjugate Program VXA-222 from Joint Discovery Collaboration with OmniAb
VXA-222 advances into next phase at VERAXA ZURICH, SWITZERLAND, July 27, 2026 -- VERAXA Biotech AG (NASDAQ: VRXA; “VERAXA” or the "Company"), an emerging leader in designing novel cancer therapies, today announced the advancement of…
VERAXA Biotech (VRXA) Presents First In Vivo Proof-of-Concept Data for BiTAC-ADC Platform at World ADC Congress
LOS ANGELES, CA - October 13, 2026 (NEWMEDIAWIRE) - VERAXA Biotech (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, presented its first in vivo proof-of-concept data and additional in vitro findings validating its…
VERAXA Biotech Appoints Raju Willener as Chief Financial Officer
Mr. Willener is an accomplished finance executive with more than three decades of international experience spanning investment banking, corporate finance, asset management and strategic leadership. Throughout his career, he has held senior…
VERAXA Biotech Provides Overview on Implementation of FDA-Aligned Human-Relevant Models into R&D Strategy
ZURICH, SWITZERLAND, Oct. 07, 2026 (GLOBE NEWSWIRE) -- VERAXA Biotech AG (NASDAQ: VRXA; “VERAXA” or the “Company”), a leading developer of next-... VERAXA Biotech Provides Overview on Implementation of FDA-Aligned Human-Relevant Models…
Veraxa Biotech appoints Raju Willener as CFO
Veraxa Biotech (VRXA) announced the appointment of Raju Willener as CFO, effective immediately. Willener will report to Christoph Antz, CEO and ... Veraxa Biotech appoints Raju Willener as CFO Veraxa Biotech (VRXA) announced the…
Veraxa Biotech, Secarna announce initial results from AOC alliance
Veraxa Biotech (VRXA) and Secarna Pharmaceuticals announced initial results from their strategic research collaboration to develop next-generati... Veraxa Biotech, Secarna announce initial results from AOC alliance Veraxa Biotech (VRXA)…
VERAXA Biotech (NASDAQ: VRXA) Advances FDA-Aligned Methods to Reduce Animal Testing
VERAXA Biotech (NASDAQ: VRXA), a developer of next-generation antibody-based cancer therapies, provided an update on ... VERAXA Biotech (NASDAQ: VRXA) Advances FDA-Aligned Methods to Reduce Animal Testing VERAXA Biotech (NASDAQ: VRXA), a…
From articles in the 4Search news index.
In the news
Mentioned with
People in the coverage
Most coverage from
-
markets.businessinsider.com6
-
investors.veraxa.com3
-
manilatimes.net2
-
citybuzz.co1
-
newmediawire.com1
Finance and business coverage in the 4Conservative news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 15 articles, not a forecast.